...
首页> 外文期刊>The journal of immunology >Acute Lymphoblastic Leukemia (ALL) Antigens Detected with Antisera to E Rosette-Forming and Non-E Rosette-Forming All Blasts
【24h】

Acute Lymphoblastic Leukemia (ALL) Antigens Detected with Antisera to E Rosette-Forming and Non-E Rosette-Forming All Blasts

机译:用抗血清检测到的形成E玫瑰花结和非E玫瑰花结的所有爆炸物的急性淋巴细胞白血病(ALL)抗原。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Based on the presence or absence of erythrocyte receptors(E) a T cell marker, acute lymphocytic leukemia (ALL), can be divided into E+ALL and E-ALL. We studied cell surface antigens on blasts from 12 children with untreated ALL: eight with E-ALL and four with E+ALL. Heterologous antisera were raised against thymus cells, E+ and E-ALL blasts, approximately absorbed and tested by immunofluorescence and a radiolabeled antibody assay with normal and leukemic lymphoid cells. By both methods, anti-thymus and anti-E+ALL sera reacted with human thymocytes. Specific binding of anti-E+ALL serum to T antigens was indicated by the fact that a single absorption with thymocytes abolished its binding to allogenic thymocytes, and the reactivity of anti-E+ALL serum with thymus, blood and bone marrow lymphocytes was similar to that of anti-thymus serum. After exhaustive absorption with blood leukocytes, anti-E+ALL and E-ALL sera were negative against normal lymphocytes and bone marrow cells from children with ALL in remission. Antithymus and anti-E+ALL sera reacted with blasts from patients with E+ALL, but not with E-ALL. In contrast, anti-E-ALL serum reacted with 40 to 96% of blasts from all children with E-ALL, whereas of the four patients with E+ALL, two were negative and two had the lowest percentage of immunofluorescent cells (10 to 22%). These results were confirmed with the radiolabeled antibody assay. Patients with active E-ALL had cells bearing E-ALL antigen(s) in the peripheral blood and bone marrow, but the number of immunofluorescent cells was lower in blood. Cells reactive with anti-E-ALL sera also were consistently found in sequential bone marrow or blood samples from children with E-ALL who had relapsed and were resistant to chemotherapy. Anti-E-ALL serum did not react with thymus cells, blood lymphocytes, remission bone marrow cells, Raji cells, PWM and PHA-induced blasts and CLL cells bearing mIg (uk). These data suggest that the antigen detected on E-ALL blasts by anti-E-ALL serum is neither a HLA-related nor a cell differentiation antigen.Thus, by using antiserum to E+ALL blasts, we have confirmed the presence of a T cell-specific antigen(s) on E+ALL cells. This antiserum did not recognize other leukemia-associated antigens common to E+ and E-ALL. We have also demonstrated an antigen(s) which is regularly expressed on E-ALL blasts and is either not detectable or is present in a lower proportion of E+ALL blasts.
机译:根据是否存在红细胞受体(E),可以将T细胞标志物急性淋巴细胞白血病(ALL)分为E + ALL和E-ALL。我们研究了来自12名未经治疗的ALL儿童的胚细胞的细胞表面抗原:八名患有E-ALL,四名患有E + ALL。产生针对胸腺细胞,E +和E-ALL母细胞的异源抗血清,大约被吸收,并通过免疫荧光和正常和白血病淋巴样细胞的放射性标记抗体测定进行测试。通过这两种方法,抗胸腺和抗E + ALL血清均与人胸腺细胞发生反应。抗-E + ALL血清与T抗原的特异性结合表明,胸腺细胞的单次吸收消除了其与异源胸腺细胞的结合,并且抗-E + ALL血清与胸腺,血液和骨髓淋巴细胞的反应性相似抗胸腺血清用血白细胞彻底吸收后,抗E + ALL和E-ALL血清对ALL缓解儿童的正常淋巴细胞和骨髓细胞呈阴性。抗胸腺和抗E + ALL血清与E + ALL患者的母细胞发生反应,但对E-ALL患者无效。相比之下,所有E-ALL儿童的抗E-ALL血清反应率为40%至96%,而4例E + ALL患者中,有2例阴性,而2例的免疫荧光细胞百分比最低(10到10%。 22%)。这些结果通过放射性标记的抗体测定法得到证实。患有活动性E-ALL的患者外周血和骨髓中都有带有E-ALL抗原的细胞,但血液中的免疫荧光细胞数量较少。在从E-ALL患儿复发且对化疗有抗药性的连续骨髓或血液样本中也始终发现与抗E-ALL血清具有反应性的细胞。抗E-ALL血清不与胸腺细胞,血液淋巴细胞,缓解性骨髓细胞,Raji细胞,PWM和PHA诱导的胚细胞以及带有mIg的CLL细胞反应。这些数据表明,抗E-ALL血清在E-ALL母细胞上检测到的抗原既不是HLA相关抗原也不是细胞分化抗原,因此,通过使用针对E + ALL母细胞的抗血清,我们证实了T的存在E + ALL细胞上的细胞特异性抗原。该抗血清不能识别E +和E-ALL常见的其他与白血病相关的抗原。我们还证明了一种抗原,该抗原在E-ALL母细胞上定期表达,或者无法检测到,或者以较低比例的E + ALL母细胞存在。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号